The Beneluxa Initiative strives to expand sustainable access for patients to high-quality affordable treatments. For this reason, the members of the Beneluxa Initiative welcome the proposed Critical Medicines Act, as it contributes to our shared goals.
The members of the Beneluxa Initiative have collectively been at the forefront of European collaboration on pharmaceutical policy and conducted multiple joint Health Technology Assessment evaluations and joint negotiations. In a recent meeting of the Beneluxa Initiative Steering Committee in Vienna in June 2025, the Committee members agreed to leverage the Initiative’s experiences in the upcoming negotiations for the benefit of the proposed Act to make it the needed tool to enhance sustainable access to high- quality and affordable treatments for patients.
The members expressed their intention to foster an open exchange within the Beneluxa Initiative on their positions. Representatives from member countries underlined that dialogue and cooperation are key determinants for the successful negotiation of this crucial piece of EU pharmaceutical policy legislation.
Last update: 2 July 2025